Metagenomic Changes of Gut Microbiota following Treatment of


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
06 Jul 2022
Historique:
received: 06 06 2022
revised: 29 06 2022
accepted: 04 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Probiotic supplementation to antibiotic regimens against To evaluate microbiota modifications due to a low-dose quadruple therapy with bismuth or Forty-six patients infected with Eradication rate was by ITT 78% in both groups, and by PP analysis 85.7% and 95.5% for Gastrus Low-dose bismuth quadruple therapy proved to be effective with lower costs and amount of antibiotics and bismuth. Gastrus

Sections du résumé

BACKGROUND BACKGROUND
Probiotic supplementation to antibiotic regimens against
AIMS OBJECTIVE
To evaluate microbiota modifications due to a low-dose quadruple therapy with bismuth or
METHODS METHODS
Forty-six patients infected with
RESULTS RESULTS
Eradication rate was by ITT 78% in both groups, and by PP analysis 85.7% and 95.5% for Gastrus
CONCLUSIONS CONCLUSIONS
Low-dose bismuth quadruple therapy proved to be effective with lower costs and amount of antibiotics and bismuth. Gastrus

Identifiants

pubmed: 35889746
pii: nu14142789
doi: 10.3390/nu14142789
pmc: PMC9316840
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Proton Pump Inhibitors 0
RNA, Ribosomal, 16S 0
Metronidazole 140QMO216E
Rabeprazole 32828355LL
Tetracycline F8VB5M810T
Bismuth U015TT5I8H

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Références

Nucleic Acids Res. 2015 Sep 3;43(15):e97
pubmed: 25925576
Int J Syst Evol Microbiol. 2020 Nov;70(11):5972-6016
pubmed: 33151140
Helicobacter. 2021 Dec;26(6):e12848
pubmed: 34448282
Infez Med. 2018 Jun 1;26(2):115-121
pubmed: 29932082
Cleve Clin J Med. 2017 Apr;84(4):310-318
pubmed: 28388387
Sci Rep. 2019 Dec 2;9(1):18111
pubmed: 31792267
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Helicobacter. 2019 Aug;24(4):e12590
pubmed: 31124220
Zhonghua Nei Ke Za Zhi. 2017 Oct 1;56(10):752-759
pubmed: 29036957
Helicobacter. 2020 Oct;25(5):e12721
pubmed: 32656891
Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):17-24
pubmed: 30791844
Gut. 2020 Sep;69(9):1572-1580
pubmed: 31974133
ISME J. 2011 Feb;5(2):169-72
pubmed: 20827291
Helicobacter. 2005;10 Suppl 1:1-4
pubmed: 16178964
Annu Rev Med. 2022 Jan 27;73:183-195
pubmed: 35084993
Can J Infect Dis Med Microbiol. 2019 Apr 01;2019:3409820
pubmed: 31065301
Helicobacter. 2019 Dec;24(6):e12659
pubmed: 31502382
Helicobacter. 2003 Aug;8(4):307-9
pubmed: 12950603
Public Health. 2020 May;182:45-50
pubmed: 32169625
Helicobacter. 2021 Dec;26(6):e12856
pubmed: 34628695
Front Pharmacol. 2022 Feb 11;13:829686
pubmed: 35222044
FEMS Immunol Med Microbiol. 2002 Jan 14;32(2):105-10
pubmed: 11821231
Nat Biotechnol. 2015 Feb;33(2):137-9
pubmed: 25658277
Clin Infect Dis. 2017 Aug 1;65(3):364-370
pubmed: 28369341
Medicine (Baltimore). 2019 Apr;98(15):e15180
pubmed: 30985706
Sci Rep. 2018 Sep 24;8(1):14241
pubmed: 30250234
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):8075-8083
pubmed: 31599433
Front Microbiol. 2019 Aug 27;10:1902
pubmed: 31507546
PLoS One. 2019 Oct 2;14(10):e0223309
pubmed: 31577828
Microb Pathog. 2020 Oct;147:104403
pubmed: 32707316
Eur J Pediatr. 2019 Jan;178(1):7-16
pubmed: 30446816
Front Cell Infect Microbiol. 2020 Jul 23;10:349
pubmed: 32793511
Gut. 2016 May;65(5):740-8
pubmed: 26657899
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Helicobacter. 2016 Jun;21(3):165-74
pubmed: 26395781
BMJ Case Rep. 2021 Feb 18;14(2):
pubmed: 33602775
Helicobacter. 2018 Aug;23(4):e12498
pubmed: 29897654
Infect Dis Ther. 2021 Mar;10(1):317-333
pubmed: 33270205
Gastroenterol Clin North Am. 2015 Sep;44(3):565-75
pubmed: 26314668
World J Gastroenterol. 2021 Jul 7;27(25):3913-3924
pubmed: 34321854
Helicobacter. 2021 Dec;26(6):e12846
pubmed: 34414638
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466-475
pubmed: 28552432
United European Gastroenterol J. 2021 Feb;9(1):38-46
pubmed: 33176617

Auteurs

Maria Pina Dore (MP)

Dipartimento di Medicina, Chirurgia e Farmacia, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.

Rosangela Sau (R)

Dipartimento di Scienze Biomediche, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.

Caterina Niolu (C)

Dipartimento di Medicina, Chirurgia e Farmacia, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.

Marcello Abbondio (M)

Dipartimento di Scienze Biomediche, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.

Alessandro Tanca (A)

Dipartimento di Scienze Biomediche, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.

Stefano Bibbò (S)

CEMAD Digestive Disease Center-Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.

Mariafrancesca Loria (M)

Dipartimento di Medicina, Chirurgia e Farmacia, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.

Giovanni Mario Pes (GM)

Dipartimento di Medicina, Chirurgia e Farmacia, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.

Sergio Uzzau (S)

Dipartimento di Scienze Biomediche, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH